Olanzapine-lnduced hyperglycemic nonketonic coma

Area of Science:

• Endocrinology
• Psychiatry
• Pharmacology

Background:

• Olanzapine is an atypical antipsychotic medication commonly used for treating schizophrenia and bipolar disorder.
• Hyperglycemia and its complications, such as hyperosmolar hyperglycemic nonketotic coma, are known risks associated with certain antipsychotic therapies.
• Weight gain is a frequently observed side effect of olanzapine, often linked to metabolic disturbances including insulin resistance.

Observation:

• A 51-year-old male patient developed extreme hyperglycemia (1596 mg/dL) and subsequently a hyperosmolar hyperglycemic nonketotic coma.
• The patient had been initiated on olanzapine therapy less than six months prior to the event.
• A notable increase in blood glucose was observed, despite a normal level recorded two months before the event.

Findings:

• Discontinuation of olanzapine therapy resulted in the normalization of the patient's serum glucose concentration within eight days.
• The patient no longer required insulin or other glucose-lowering agents after stopping olanzapine.
• The case suggests olanzapine may induce hyperglycemia through mechanisms beyond weight gain, potentially indicating direct effects on glucose metabolism.

Implications:

• Clinicians should be vigilant for the development of hyperglycemia in patients treated with olanzapine, even in the absence of significant weight gain.
• This case highlights the potential for olanzapine to cause severe metabolic derangements, necessitating careful patient monitoring.
• Further research into the specific mechanisms by which olanzapine affects glucose homeostasis is warranted to better manage patient safety.